Cargando…

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus

Diabetes mellitus is a leading cause of morbidity and mortality and a significant risk factor for the early onset of chronic kidney disease and heart disease. Hyperglycemia and insulin resistance are key factors that play a role in the pathogenesis of type 2 diabetes. Renal glucose reabsorption is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srinivas, Natasha, Sarnaik, Mubashira K, Modi, Srimy, Pisipati, Yasaswi, Vaidya, Sarayoo, Syed Gaggatur, Naqvi, Sange, Aliya H, Sange, Ibrahim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414630/ https://www.ncbi.nlm.nih.gov/pubmed/34513443 http://dx.doi.org/10.7759/cureus.16868

Ejemplares similares

Proton Pump Inhibitors: Exploring Cardiovascular Complications and Prescription Protocol
por: Sarnaik, Mubashira K, et al.
Publicado: (2021)

Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening
por: Syed Gaggatur, Naqvi, et al.
Publicado: (2021)

Extra-Intestinal Manifestations of Inflammatory Bowel Disease
por: Sange, Aliya H, et al.
Publicado: (2021)

“Are We Feeding Them Enough?” Micronutrient Deficiency in Children Aged Six Months to Fourteen Years in India
por: Vaidya, Sarayoo R, et al.
Publicado: (2021)

An Emerging Facet of Diabetes Mellitus: The Nexus of Gastrointestinal Disorders
por: Modi, Srimy, et al.
Publicado: (2021)

Sickle Cell Disease and the Respiratory System: A Tangential Perspective to the Hematopulmonological Dilemma
por: Sange, Ibrahim, et al.
Publicado: (2021)

Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go
por: Gajjela, Harini, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience
por: Shah, Bhupesh R, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review
por: Wahinya, Maureen, et al.
Publicado: (2023)

Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials
por: Jamil, Sidra, et al.
Publicado: (2022)

Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review
por: Palyam, Vishnu, et al.
Publicado: (2022)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
por: Kluger, Aaron Y., et al.
Publicado: (2019)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Cardiorenal Syndrome: A Literature Review
por: Ajibowo, Abimbola O, et al.
Publicado: (2023)

A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection
por: Raza, Shafaat, et al.
Publicado: (2022)

Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review
por: Sarker, Aditi, et al.
Publicado: (2022)

A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022)

Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management
por: Verma, Deepak, et al.
Publicado: (2021)

Cardiovascular Involvement in Thyrotoxicosis Resulting in Heart Failure: The Risk Factors and Hemodynamic Implications
por: Raguthu, Ciri C, et al.
Publicado: (2022)

Beyond the Skin Plaques: Psoriasis and Its Cardiovascular Comorbidities
por: Kakarala, Chandra L, et al.
Publicado: (2021)

Systemic Lupus Erythematosus and Cardiovascular Disease
por: Jha, Surajkumar B, et al.
Publicado: (2022)

Risk of Stroke With Mitral Stenosis: The Underlying Mechanism, Treatment, and Prevention
por: Islam, Hamza, et al.
Publicado: (2022)

Coronary Artery Calcium Score - A Reliable Indicator of Coronary Artery Disease?
por: Shreya, Devarashetty, et al.
Publicado: (2021)

Hereditary Hemochromatosis: A Cardiac Perspective
por: Joshi, Pranay K, et al.
Publicado: (2021)

Panoramic Dominance of the Immune System in Cardiorenal Syndrome Type I
por: Peesapati, Venkata Sri Ramani, et al.
Publicado: (2020)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients
por: Balan, Irina, et al.
Publicado: (2021)

SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
por: Wang, Yajiao, et al.
Publicado: (2023)

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus
por: Rehman, Saad U, et al.
Publicado: (2020)

Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure
por: Choday, Silpa, et al.
Publicado: (2023)

Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function
por: Lee, Hong Kyu
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review
por: Giri Ravindran, Suganya, et al.
Publicado: (2022)

The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review
por: Thiagaraj, Suvedha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1honcf72rh071eu0gs7u22af4l